Trials / Completed
CompletedNCT00219817
Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (planned)
- Sponsor
- Helsinn Therapeutics (U.S.), Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Anorexia and weight loss are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated to stimulate appetite. RC-1291 HCl, by virtue of its ghrelin like activity and Growth Hormone releasing effects may have a dual role in the reversal of cancer induced anorexia and weight loss. This study will test the safety and efficacy of RC-1291 in the treatment of cancer patients with anorexia and weight loss.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RC-1291 HCl |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2006-10-01
- Completion
- 2006-10-01
- First posted
- 2005-09-22
- Last updated
- 2013-09-02
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00219817. Inclusion in this directory is not an endorsement.